ORAMED PHARMACEUTICALS INC.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
ORMP$4.00+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Equity
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
U.S. Dollars in thousands
| Common Stock · Additional paid-in · Accumulated · Total stockholders’ · Non- controlling · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares | $ | capital | deficit | equity | interests | equity | |
| In thousands | |||||||
| BALANCE AS OF DECEMBER 31, 2024 | 39,920 | $480 | $322,401 | $(176,616) | $146,265 | $(918) | $145,347 |
| CHANGES DURING THE SIX MONTH PERIOD ENDED JUNE 30, 2025: | |||||||
| STOCK-BASED COMPENSATION | 1,089 | 13 | 2,976 | - | 2,989 | - | 2,989 |
| REPURCHASE AND RETIREMENT OF COMMON STOCK | (164) | (2) | (369) | - | (371) | - | (371) |
| NET INCOME | - | - | - | 5,646 | 5,646 | (28) | 5,618 |
| BALANCE AS OF JUNE 30, 2025 | 40,845 | $491 | $325,008 | $(170,970) | $154,529 | $(946) | $153,583 |
| Common Stock · Additional paid-in · Accumulated · Total stockholders’ · Non- controlling · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares | $ | capital | deficit | equity | interests | equity | |
| In thousands | |||||||
| BALANCE AS OF DECEMBER 31, 2023 | 40,339 | $485 | $320,892 | $(157,556) | $163,821 | $(928) | $162,893 |
| CHANGES DURING THE SIX MONTH PERIOD ENDED JUNE 30, 2024: | |||||||
| STOCK-BASED COMPENSATION | 290 | 3 | 2,493 | - | 2,496 | - | 2,496 |
| STOCK-BASED COMPENSATION OF SUBSIDIARY | - | - | - | - | - | 27 | 27 |
| NET INCOME | - | - | - | 10,748 | 10,748 | (10) | 10,738 |
| BALANCE AS OF JUNE 30, 2024 | 40,629 | $488 | $323,385 | $(146,808) | $177,065 | $(911) | $176,154 |
| Common Stock · Additional paid-in · Accumulated · Total stockholders’ · Non- controlling · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares | $ | capital | deficit | equity | interests | equity | |
| In thousands | |||||||
| BALANCE AS OF MARCH 31, 2025 | 40,851 | $491 | $324,579 | $(184,258) | $140,812 | $(918) | $139,894 |
| CHANGES DURING THE THREE MONTH PERIOD ENDED JUNE 30, 2025: | |||||||
| STOCK-BASED COMPENSATION | 158 | 2 | 798 | - | 800 | - | 800 |
| REPURCHASE AND RETIREMENT OF COMMON STOCK | (164) | (2) | (369) | - | (371) | - | (371) |
| NET INCOME | - | - | - | 13,288 | 13,288 | (28) | 13,260 |
| BALANCE AS OF JUNE 30, 2025 | 40,845 | $491 | $325,008 | $(170,970) | $154,529 | $(946) | $153,583 |
| Common Stock · Additional paid-in · Accumulated · Total stockholders’ · Non- controlling · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares | $ | capital | deficit | equity | interests | equity | |
| In thousands | |||||||
| BALANCE AS OF MARCH 31, 2024 | 40,519 | $487 | $322,172 | $(156,020) | $166,639 | $(918) | $165,721 |
| CHANGES DURING THE THREE MONTH PERIOD ENDED JUNE 30, 2024: | |||||||
| STOCK-BASED COMPENSATION | 110 | 1 | 1,213 | - | 1,214 | - | 1,214 |
| STOCK-BASED COMPENSATION OF SUBSIDIARY | - | - | - | - | - | 15 | 15 |
| NET INCOME | - | - | - | 9,212 | 9,212 | (8) | 9,204 |
| BALANCE AS OF JUNE 30, 2024 | 40,629 | $488 | $323,385 | $(146,808) | $177,065 | $(911) | $176,154 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.